Comparison of the Pharmacokinetic Properties of Hemoglobin-Based Oxygen Carriers
Source abstract
Abstract
Hemoglobin (Hb) is an ideal material for use in the development of an oxygen carrier in view of its innate biological properties. However, the vascular retention of free Hb is too short to permit a full therapeutic effect because Hb is rapidly cleared from the kidney via glomerular filtration or from the liver via the haptogloblin-CD 163 pathway when free Hb is administered in the blood circulation. Attempts have been made to develop alternate acellular and cellular types of Hb based oxygen carriers (HBOCs), in which Hb is processed via various routes in order to regulate its pharmacokinetic properties. These HBOCs have been demonstrated to have superior pharmacokinetic properties including a longer half-life than the Hb molecule in preclinical and clinical trials. The present review summarizes and compares the pharmacokinetic properties of acellular and cellular type HBOCs that have been developed through different approaches, such as polymerization, PEGylation, cross-linking, and encapsulation.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Hemoglobin structure and function · Heme Oxygenase-1 and Carbon Monoxide · Nitric Oxide and Endothelin Effects
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Faculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 862-0082, Japan
DDS Research Institute, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 862-0082, Japan
Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan
Center for Clinical Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan
References (100+)
Show source-provided references
1. Does prolonged storage of red blood cells cause harm?10.1111/bjh.12747 ↗
2. A review of blood substitutes: Examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers10.1590/S1807-59322009000800016 ↗
3. Crosslinked, polymerized, and peg-conjugated hemoglobin-based oxygen carriers: Clinical safety and efficacy of recent and current products10.2174/157016312802650742 ↗
4. Hboc-201, hemoglobin glutamer-250 (bovine), hemopure (biopure corporation)10.1517/14712598.8.9.1425 ↗
5. A clinical safety trial of stroma-free hemoglobin10.1002/cpt197823173 ↗
6. Hemoglobin-based oxygen carriers: From mechanisms of toxicity and clearance to rational drug design10.1016/j.molmed.2010.07.006 ↗
7. The renal handling of hemoglobin. I. Glomerular filtration10.1084/jem.129.5.909 ↗
8. Identification of the haemoglobin scavenger receptor10.1038/35051594 ↗
9. A human recombinant haemoglobin designed for use as a blood substitute10.1038/356258a0 ↗
10. Recombinant human hemoglobin does not affect renal function in humans: Analysis of safety and pharmacokinetics10.1097/00000542-199704000-00015 ↗
11. A double-blind study to evaluate the safety of recombinant human hemoglobin in surgical patients during general anesthesia10.1053/jcan.2001.26538 ↗
12. Resuscitation with recombinant hemoglobin rHB2.0 in a rodent model of hemorrhagic shock10.1097/01.anes.0000270756.11669.64 ↗
13. Effects of recombinant-hemoglobin solutions rHB2.0 and rHB1.1 on blood pressure, intestinal blood flow, and gut oxygenation in a rat model of hemorrhagic shock10.1016/j.lab.2004.05.017 ↗
14. Monodisperse 130 KDa and 260 KDa recombinant human hemoglobin polymers as scaffolds for protein engineering of hemoglobin-based oxygen carriers10.3390/jfb3010061 ↗
15. Freytag, J.W., Caspari, R.F., and Gorczynski, R.J. (1998). Blood Substitutes, Present and Future Perspectives, Elsevier Science.
16. Artificial oxygen carriers as red blood cell substitutes: A selected review and current status10.1111/j.1525-1594.2004.07345.x ↗
17. The role of the kidneys in the excretion of chemically modified hemoglobins
18. Enhanced oxygen unloading by an interdimerically crosslinked hemoglobin in an isolated perfused rabbit heart10.1073/pnas.81.9.2941 ↗
19. Oxygen affinity of hemoglobin solutions modified by coupling with NFPLP and the effects on tissue oxygenation in the isolated perfused rat liver10.1007/978-1-4684-3291-6_48 ↗
20. Effect of coupling of 2-nor-2-formylpyridoxal 5′-phosphate to stroma-free hemoglobin on oxygen affinity and tissue oxygenation. Studies in the isolated perfused rat liver under conditions of normoxia and stagnant hypoxia
21. Prolonged vascular retention of a hemoglobin solution modified by cross-linking with 2-nor-2-formylpyridoxal 5′-phosphate
22. Plasma retention and metabolic fate of hemoglobin modified with an interdimeric covalent cross link10.1097/00002216-198904000-00007 ↗
23. In vivo distribution and elimination of hemoglobin modified by intramolecular cross-linking with 2-nor-2-formylpyridoxal 5′-phosphate
24. Acute changes in systemic blood pressure and urine output of conscious rats following exchange transfusion with diaspirin-crosslinked hemoglobin solution10.1046/j.1537-2995.1993.33994025016.x ↗
25. Diaspirin cross-linked hemoglobin: Tissue distribution and long-term excretion after exchange transfusion
26. Influence of sepsis on the plasma elimination pharmacokinetics of diaspirin crosslinked hemoglobin in rats10.3109/10731199809117458 ↗
27. Pharmacokinetics of diaspirin cross-linked haemoglobin in a rat model of hepatic cirrhosis10.1211/0022357011775370 ↗
28. Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution10.1097/00003246-199612000-00011 ↗
29. Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients10.1016/0272-6386(95)90056-X ↗
30. Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery10.1097/00000542-200003000-00007 ↗
31. Hemoglobin and methemoglobin concentrations after large-dose infusions of diaspirin cross-linked hemoglobin10.1097/00000539-200101000-00009 ↗
32. Rentko, V.T., Pearce, L.B., Moon-Massat, P.F., and Gawryl, M.S. (2006). Blood Substitutes, Elsevier.
33. Effects of bovine polymerized hemoglobin on coagulation in controlled hemorrhagic shock in swine10.1097/01.shk.0000170354.18437.2f ↗
34. Pearce, L.B., Gawryl, M.S., Rentko, V.T., Moon-Massat, P.F., and Rausch, C.W. (2006). Blood substitutes, Elsevier.
35. Physiology and pharmacokinetics of a novel hemoglobin-based oxygen carrier in humans10.1097/00003246-199605000-00006 ↗
36. Hemoglobin-based oxygen carrier preserves submaximal exercise capacity in humans10.1016/0009-9236(95)90057-8 ↗
37. Hematologic effects of a novel hemoglobin-based oxygen carrier in normal male and female subjects
38. Bovine haemoglobin-based oxygen carrier for patients undergoing haemodilution before liver resection10.1093/bja/80.2.189 ↗
39. Blood product from cattle wins approval for use in humans10.1038/35073775 ↗
40. Hemoglobin glutamer-250 (bovine) in south africa: Consensus usage guidelines from clinician experts who have treated patients10.1111/trf.13726 ↗
41. O-raffinose-polymerised haemoglobin. A biochemical and pharmacological profile of an oxygen carrier10.1517/14712598.1.1.121 ↗
42. Pharmacokinetic studies in the rat on a O-raffinose polymerized human hemoglobin
43. Pharmacokinetics of 3h-hemolinktm in rats
44. The intravascular persistence and methemoglobin formation of hemolink (hemoglobin raffimer) in dogs10.1081/BIO-120018000 ↗
45. A phase I study of oxidized raffinose cross-linked human hemoglobin10.1097/00003246-200007000-00017 ↗
46. A phase ii dose-response study of hemoglobin raffimer (hemolink) in elective coronary artery bypass surgery10.1016/j.jtcvs.2003.08.024 ↗
47. Use of an oxygen therapeutic as an adjunct to intraoperative autologous donation to reduce transfusion requirements in patients undergoing coronary artery bypass graft surgery10.1016/j.jamcollsurg.2003.11.020 ↗
48. Safety and preliminary efficacy of hemoglobin raffimer for patients undergoing coronary artery bypass surgery10.1053/jcan.2002.128416 ↗
49. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable10.1016/S1072-7515(02)01335-2 ↗
50. Human haemoglobin-northfield
51. Polymerized pyridoxylated hemoglobin: A red cell substitute with normal oxygen capacity
52. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery10.1016/S1072-7515(98)00095-7 ↗
53. Hemospan: Design principles for a new class of oxygen therapeutic10.1111/j.1525-1594.2008.00697.x ↗
54. Mp4, a new nonvasoactive peg-hb conjugate10.1046/j.1537-2995.2003.00341.x ↗
55. Toxicity and hemodynamic effects after single dose administration of malpeg-hemoglobin (mp4) in rhesus monkeys10.1016/j.trsl.2006.09.007 ↗
56. A phase I single blind clinical trial of a new oxygen transport agent (mp4), human hemoglobin modified with maleimide-activated polyethylene glycol
57. A randomized, single-blind, increasing dose safety trial of an oxygen-carrying plasma expander (hemospan) administered to orthopaedic surgery patients with spinal anaesthesia10.1111/j.1365-3148.2007.00811.x ↗
58. A multicenter clinical study of the safety and activity of maleimide-polyethylene glycol-modified hemoglobin (hemospan) in patients undergoing major orthopedic surgery10.1097/00000542-200612000-00015 ↗
59. The effects of hemodilution with polyethylene glycol bovine hemoglobin (PEG-Hb) in a conscious porcine model
60. Comparison of the efficacy of blood and polyethylene glycol-hemoglobin in recovery of newborn piglets from hemorrhagic hypotension: Effect on blood pressure, cortical oxygen, and extracellular dopamine in the brain10.1046/j.1537-2995.1995.35795357876.x ↗
61. Effect of polyethylene glycol conjugated bovine hemoglobin in both top-load and exchange transfusion rat models10.1111/j.1525-1594.1997.tb00444.x ↗
62. The ability of polyethylene glycol conjugated bovine hemoglobin (PEG-Hb) to adequately deliver oxygen in both exchange transfusion and top-loaded rat models10.3109/10731199909117685 ↗
63. The impact of polyethylene glycol conjugation on bovine hemoglobin’s circulatory half-life and renal effects in a rabbit top-loaded transfusion model10.1111/j.1525-1594.1997.tb00250.x ↗
64. Physiological effect of polyethylene glycol conjugation on stroma-free bovine hemoglobin in the conscious dog after partial exchange transfusion10.1111/j.1525-1594.1997.tb00733.x ↗
65. Peg-bovine hemoglobin: Safety in a canine dehydrated hypovolemic-hemorrhagic shock model
66. Neuroprotective effects of the novel polyethylene glycol-hemoglobin conjugate SB1 on experimental cerebral thromboembolism in rats10.1016/j.ejphar.2007.02.061 ↗
67. Pharmacokinetics of 125I-radiolabelled PEG-hemoglobin SB110.1080/10731190600683779 ↗
68. Pharmacokinetics of PEG-hemoglobin SB1, a hemoglobin-based oxygen carrier, after its intravenous administration in beagle dogs10.1007/BF02980115 ↗
69. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: A meta-analysis10.1001/jama.299.19.jrv80007 ↗
70. Haemoglobin-based oxygen carriers: Indications and future applications10.12968/hmed.2015.76.2.78 ↗
71. Razynska, A., and Bucci, E. (1998). Blood Substitutes, Present and Future Perspectives, Elsevier Science.
72. Kim, H.W., and Greenburg, A.G. (2013). Hemoglobin-Based Oxygen Carriers as Red Cell Substitutes and Oxygen Therapeutics, Springer Berlin Heidelberg.10.1007/978-3-642-40717-8 ↗
73. Molecular design properties of oxyvita hemoglobin, a new generation therapeutic oxygen carrier: A review10.3390/jfb2040414 ↗
74. Wollocko, H., Anvery, S., Wollocko, J., Harrington, J.M., and Harrington, J.P. (2016). Zero-link polymerized hemoglobin (OxyVita®Hb) stabilizes the heme environment: Potential for lowering vascular oxidative stress. Artif. Cells Nanomed. Biotechnol., 1–9.10.1080/21691401.2016.1263639 ↗
75. Pre-clinical studies using oxyvita hemoglobin, a zero-linked polymeric hemoglobin: A review10.1007/s10047-010-0528-6 ↗
76. Physicochemical characteristics of oxyvita hemoglobin, a zero-linked polymer: Liquid and powder preparations10.3109/10731199.2010.501753 ↗
77. Vascular response to infusions of a nonextravasating hemoglobin polymer10.1152/japplphysiol.00191.2002 ↗
78. Pegylated bovine carboxyhemoglobin (sanguinate): Results of clinical safety testing and use in patients10.1007/978-1-4939-3023-4_58 ↗
79. Carbon monoxide form of pegylated hemoglobin protects myocardium against ischemia/reperfusion injury in diabetic and normal mice10.3109/21691401.2012.762370 ↗
80. Sanguinate’s effect on pial arterioles in healthy rats and cerebral oxygen tension after controlled cortical impact10.1016/j.mvr.2016.06.001 ↗
81. Transfusion of hemoglobin-based oxygen carriers in the carboxy state is beneficial during transient focal cerebral ischemia10.1152/japplphysiol.01079.2012 ↗
82. Pegylated carboxyhemoglobin bovine (sanguinate): Results of a phase i clinical trial10.1111/aor.12341 ↗
83. A phase Ib open label, randomized, safety study of SANGUINATE™ in patients with sickle cell anemia10.1016/j.bjhh.2016.08.004 ↗
84. Microglia regulate blood clearance in subarachnoid hemorrhage by heme oxygenase-110.1172/JCI78443 ↗
85. Co-mp4, a polyethylene glycol-conjugated haemoglobin derivative and carbon monoxide carrier that reduces myocardial infarct size in rats10.1038/bjp.2008.219 ↗
86. MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice10.1182/blood-2013-02-486282 ↗
87. Clinical evaluation of MP4CO: A phase 1b escalating-dose, safety and tolerability study in stable adult patients with sickle cell disease10.1007/978-3-319-38810-6_3 ↗
88. Covalent core-shell architecture of hemoglobin and human serum albumin as an artificial O2 carrier10.1021/bm400204y ↗
89. Safety evaluation of hemoglobin-albumin cluster "HemoAct" as a red blood cell substitute10.1038/srep12778 ↗
90. Yamada, K., Yokomaku, K., Haruki, R., Taguchi, K., Nagao, S., Maruyama, T., Otagiri, M., and Komatsu, T. (2016). Influence of molecular structure on O2-binding properties and blood circulation of hemoglobinalbumin clusters. PLoS ONE, 11.10.1371/journal.pone.0149526 ↗
91. Albumin clusters: Structurally defined protein tetramer and oxygen carrier including thirty-two iron(II) porphyrins10.1021/bm050454u ↗
92. Hosaka, H., Haruki, R., Yamada, K., Bottcher, C., and Komatsu, T. (2014). Hemoglobin-albumin cluster incorporating a pt nanoparticle: Artificial O2 carrier with antioxidant activities. PLoS ONE, 9.10.1371/journal.pone.0110541 ↗
93. Clinical use of a haemoglobin-based oxygen-carrying solution in dogs and cats10.1136/inpract.27.8.399 ↗
94. Artificial blood for dogs10.1038/srep36782 ↗
95. Review of hemoglobin-vesicles as artificial oxygen carriers10.1111/j.1525-1594.2008.00698.x ↗
96. Haemoglobin-vesicles as artificial oxygen carriers: Present situation and future visions10.1111/j.1365-2796.2007.01893.x ↗
97. Liposome-encapsulated hemoglobin, TRM-645: Current status of the development and important issues for clinical application10.1111/j.1525-1594.2008.00699.x ↗
98. Surface modification of haemoglobin-containing liposomes with polyethylene glycol prevents liposome aggregation in blood plasma10.1016/0142-9612(91)90075-L ↗
99. Large scale production of neo red cell
100. Effect of liposome-encapsulated hemoglobin, neo red cells, on hemorrhagic shock10.1007/BF02483956 ↗